Hypoxia-inducible factor–prolyl hydroxylase domain inhibitors (HIF-PHIs) are a new class of oral drugs for the treatment of anemia in CKD patients. They demonstrate comparable efficacy to erythropoietin-stimulating agents (ESA) in anemia correction and maintenance. Despite expectations, they have not shown better outcomes compared to ESA. This webinar starts with a clinical case and proposes some points of reflection on which patients could be candidates for the use of this new class of drugs.

This webinar was moderated by David Wheeler, MD (United Kingdom), and featured speakers Volker Haase, MD (United States), and Lucia Del Vecchio, MD (Italy). The webinar took place on July 20, 2023.